Xia Xue

Xia Xue

Auto-generated profile, based on publicly available information

Xia Xue

Research Center for Nano Biomaterials, Analytical & Testing Center, Sichuan University, Chengdu, Sichuan, People’s Republic of China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Applied Biomaterials & Functional Materials
Verified
Journal Article
Open access
PDF file
XXXue Xia
Xue Xia
RSRui Shi
Rui Shi
JHJinhui Huang
Jinhui Huang
YLYubao Li
Yubao Li
YZYi Zuo
Yi Zuo
JLJidong Li
Jidong Li
The aim of the current study is to alleviate the adverse effect of the strongly exothermic polymerization of polymethyl methacrylate (PMMA) bone cement in clinical applications. In this study, paraffin/poly(methyl methacrylate–methylene bisacrylamide) (paraffin/P(MMA-MBA)) phase change microcapsules (MPn; n = 1, 2) were developed via the emulsion polymerization method. The reduction of the maximum temperature of polymerization (Tmax) and physicochemical properties were evaluated after doping commercial PMMA cement with MPn in specific proportions (10%, 20%, and 30%). The results reveal that the MPn-doped PMMA exhibited an effective reduction in Tmax, which can help alleviate the adverse effect of the strong exothermic reactions during PMMA setting. After doping with the MPn, the mechanical properties of the PMMA cement decrease and the values are close to that of body cancellous bone. The Tmax of the cement doped with 20 wt% MP1 is 37.6°C, which is close to body temperature. Significantly, the setting and compressive properties of the optimized group can still adhere to clinical requirements. The MPn doping PMMA technique holds much promise in clinical practice.

23 September 2011 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
YCYuan Chao
Yuan Chao
YZYu-Sheng Zhang
Yu-Sheng Zhang
YCYan-Na Cheng
Yan-Na Cheng
XXXia Xue
Xia Xue
WXWen-Fang Xu
Wen-Fang Xu
XQXian-Jun Qu
Xian-Jun Qu
A112 is a tamibarotene dimethylaminoethyl ester considered a candidate compound for the treatment of acute promyelocytic leukemia (APL) and acute myeloid leukemia (AML). Our goal in this study was to evaluate the efficacy of anti-cancer activity, beginning by studying its inhibitory effects on leukemia cells and then comparing it to tamibarotene. A112 effectively inhibited the growth of HL-60 and NB4 cells as estimated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The inhibitory effect of A112 was confirmed in mice in which A112 delayed the growth of HL-60 xenografts after 3 weeks’ injection. The efficacy of A112 on leukemia cell growth was stronger than that of tamibarotene at the same dosage. The detection of A112 and tamibarotene in plasma of rats showed that A112 might sustain release of its hydrolysate tamibarotene, and the concentration was maintained at a higher level and for a longer time than that of tamibarotene injection. We studied the differentiation morphologies of leukemic cells exposed to A112 or tamibarotene. The number of differentiated NB4 cells was increased, suggesting that A112 possessed differentiation activity in the inhibition of leukemia growth. Further studies showed that the expression of CD11b, a marker of terminal granulocyte differentiation, was increased as estimated by flow cytometry with a direct immunofluorescence assay. A112 was found to induce the activation of CCAAT/enhancer-binding protein β (C/EBPβ) and cyclin-dependent kinase (CDK) inhibitors p21Waf1/cip1 and p27Kip1 while cell growth was inhibited. These activities of A112 were greater than those of tamibarotene. The higher efficacy of A112 was also evidenced by induction of apoptosis in leukemia cells. A112 induced a greater number of annexin V-positive cells than did tamibarotene as measured by flow cytometry analysis. Treatment of mice with A112 resulted in stronger terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining in HL-60 xenografts. Western blot analysis revealed that A112 increased the expression of caspase-3, caspase-9 and cleaved poly(ADP-ribose) polymerase (PARP) in leukemia cells both in vitro and in vivo, indicating that induction of apoptosis was involved in the inhibition of leukemia growth. Taken together, these results suggest that A112 is a highly effective derivative of trans retinoic acid and a potential candidate compound for the treatment of leukemia.

15 January 2026 in Applied Surface Science
Verified
Journal Article
Closed access
XXXue Xia
Xue Xia
JHJinhui Huang
Jinhui Huang
SXShiqi Xiao
Shiqi Xiao
JWJiawei Wei
Jiawei Wei
YDYichen Dou
Yichen Dou
Jidong LiJidong Li
Jidong Li

6 July 2023 in Gastroenterology
Verified
Journal Article
Closed access
YMYang Mi
Yang Mi
XXXia Xue
Xia Xue
CTChin Yen Tay
Chin Yen Tay
BMBarry Marshall
Barry Marshall
PZPengyuan Zheng
Pengyuan Zheng